Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Efficacy and safety evaluation of tolvaptan in the treatment of patients with right heart failure caused by pulmonary arterial hypertension

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Chinese Pulmonary Vascular Disease Research Group
• Treatments: Furosemide; Tolvaptan

Criteria

Inclusion Criteria:

• Patients who have no serious cerebrovascular, liver, kidney and lung organ and tissue diseases.

• No corticosteroids or immunosuppressive agents had been administered to the - Patients in the three months prior to enrollment in the study.

• Patients voluntarily participated in the study and signed an informed consent form.

Exclusion Criteria:

• Patients who install the circulation aids.

• Patients who have been diagnosed with active myocarditis or amyloid cardiomyopathy.

• Fasting blood glucose level exceeded 12.21 mmol/L in individuals with uncontrolled diabetes.

• Patients who suffer from anuria, urethral strictures, stones, or tumors caused by urination disorders.

• Patients with acute myocardial infarctions, persistent ventricular tachycardias, or ventricular fibrillations, and cerebrovascular accidents within the first 30 days of the screening period.

• Patients with a history of allergy or specific reactions to benzodiazepines. (Mozavaputan hydrochloride, Benaepril hydrochloride)

• Any of the following laboratory tests were abnormal: serum creatinine> 2.5 times the upper normal value limit, serum sodium> 145 mmol/L, and serum potassium> 5.5 mmol/L.

• Pregnant women, lactating women, or patients who may be pregnant or have pregnancy plans.

• Patients with other contraindications to the use of tolvaptan.

• Patients who have been taking tolvaptan within the first 3 months before inclusion in the study, either when the drug was marketed or when it was being clinically studied.

• Additionally, patients who were judged by the investigators not fit to be enrolled in this trial.